PEPTIDE

Retatrutide

Triple agonist at GLP-1, GIP, and glucagon receptors; Phase 2 demonstrated up to 24% body weight reduction at 48 weeks.

BIOGATE · GREEN | POSTERIOR 82.3% | MW 4731.5 | 39AA

SEQUENCE

YXQGTFTSDYSIYLDKQAAXEFVNWLLAGGPSSGAPPPS

Modifications: Aib[2]; Aib[13]; ε-Glu-C20 lipid sidechain; amidated C-terminus

PDA-V1 chain of custody

Outer hash

```
151-ba431141ba29e131ba10b121b9f78191baa7d181ba8ea171ba75716
```

Merkle root

```
058-d5a7a068d5c0d038d5754048d58e7018d542e028d55c1ff8d5108008d529b
```

Inputs

```
97-c8e1b196c8e01e95c8de8b94c8dcf89bc8e7fd9ac8e66a99c8e4d79
```

TEE attestation

```
8-fbcd1c890bcd35b91bcd4ee92bcd68193bcd81494bcd9a795bcdb3a96bcd-ccd
```

Living Outcome Oracle

± =63.7 ² =13.8 **P(success) = 82.3%**

95% CI [70.3%, 94.3%]

Seven-rule export gate

7 / 7 rules satisfied · audience: researcher · Full attestation set, raw posteriors, all hashes

- Grade A or B citation present on the core claim
- BioGate verdict is GREEN or AMBER (RED/BLACK refused)
- Jurisdiction permits the audience-appropriate use
- RWE summary attached when claim depends on outcome data
- Prediction-outcome pairs disclosed when posterior cited
- No human-use claim beyond cited indications
- COA registry lookup available for any synthesis claim

Citations

GRADE A — 2023 · N Engl J Med

Triple-Hormone-Receptor Agonist Retatrutide for Obesity (Phase 2)

Jastreboff AM et al.

DOI 10.1056/NEJMoa2301972